What is Zenbexus (iberdomide) — first CELMoD therapy?

Zenbexus (iberdomide) is an oral small-molecule therapy in the cereblon E3 ligase modulator (CELMoD) drug class, which binds the cereblon protein within the E3 ubiquitin ligase complex to redirect it toward disease-linked target proteins, marking them for degradation by the cell's normal protein-disposal machinery. This targeted-degradation mechanism is designed to modulate immune and hematologic signaling pathways with refined selectivity, making the compound relevant to research in blood cancers and autoimmune conditions.